Lv12
10 积分 2025-04-01 加入
Hidradenitis Suppurativa from a Multi-Omic Scope
7小时前
待确认
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
11小时前
已完结
Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics
12小时前
已完结
Hidradenitis Suppurativa Preclinical Studies: Models and Results
15天前
已完结
The preclinical discovery and development of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa
15天前
已完结
An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity
21天前
已关闭
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
29天前
已完结
Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts
29天前
已关闭
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
1个月前
已完结
皖公网安备34019202002308
